We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+2.79%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$511M
AUM Growth
+$1.51M
Cap. Flow
-$202K
Cap. Flow %
-0.04%
Top 10 Hldgs %
52.15%
Holding
56
New
12
Increased
14
Reduced
11
Closed
16

Top Buys

Rank Stock Value
1
ZURA icon
Zura Bio
ZURA
+$26.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$15.9M
3
ALKS icon
Alkermes
ALKS
+$12.5M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$12.2M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$8.38M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$21.9M
2
TVTX icon
Travere Therapeutics
TVTX
+$17.2M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$16.9M
4
KALV
KalVista Pharmaceuticals
KALV
+$12.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
1
DELISTED
Alpine Immune Sciences Inc
ALPN
$34.6M 6.77%
3,363,688
-377,073
-10% -$3.4M
RARE icon
2
Ultragenyx Pharmaceutical
RARE
$2.45B
$31.2M 6.12%
677,426
– –
PCVX icon
3
Vaxcyte
PCVX
$7.81B
$29.4M 5.76%
589,211
-70,000
-11% -$3.32M
PLRX icon
4
Pliant Therapeutics
PLRX
$64.4M
$28.1M 5.5%
1,550,184
+338,088
+28% +$8M
RAPT
5
DELISTED
RAPT Therapeutics
RAPT
$27.4M 5.36%
183,144
+13,750
+8% +$2.14M
PNT
6
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$27.2M 5.32%
3,000,000
-383,029
-11% -$3.38M
ZURA icon
7
Zura Bio
ZURA
$516M
$27M 5.29%
+3,295,000
New +$26.5M
AMLX icon
8
Amylyx Pharmaceuticals
AMLX
$2.26B
$20.9M 4.09%
968,795
+185,000
+24% +$5M
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.06B
$20.4M 3.99%
530,000
-288,505
-35% -$11.5M
ACRS icon
10
Aclaris Therapeutics
ACRS
$726M
$20.1M 3.94%
1,941,581
+750,000
+63% +$6.79M
CYTK icon
11
Cytokinetics
CYTK
$10.5B
$19.6M 3.83%
600,000
+100,000
+20% +$3.7M
ANAB icon
12
AnaptysBio
ANAB
$1.58B
$18.2M 3.56%
894,333
+90,000
+11% +$1.82M
IMCR icon
13
Immunocore
IMCR
$1.72B
$17.8M 3.49%
297,082
+41,715
+16% +$2.38M
EOLS icon
14
Evolus
EOLS
$385M
$17.7M 3.46%
2,434,048
+241,232
+11% +$2.08M
JBIO
15
Jade Biosciences
JBIO
$1.2B
$16M 3.13%
26,633
+5,044
+23% +$3.23M
SRPT icon
16
Sarepta Therapeutics
SRPT
$1.57B
$14.2M 2.77%
+123,600
New +$15.9M
ALKS icon
17
Alkermes
ALKS
$8.22B
$12.9M 2.52%
+411,453
New +$12.5M
RYTM icon
18
Rhythm Pharmaceuticals
RYTM
$6.81B
$12.7M 2.49%
772,000
+674,456
+691% +$12.2M
OPTN
19
DELISTED
OptiNose
OPTN
$10.9M 2.13%
589,329
+63,013
+12% +$1.49M
VKTX icon
20
Viking Therapeutics
VKTX
$3.7B
$9.7M 1.9%
598,550
-401,450
-40% -$8.41M
MLYS icon
21
Mineralys Therapeutics
MLYS
$2.25B
$9.31M 1.82%
546,059
-74,267
-12% -$1.11M
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$8.81M 1.72%
701,392
+321,392
+85% +$3.81M
GRCL
23
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$8.64M 1.69%
2,268,057
-885,149
-28% -$2.48M
APLS
24
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$8.63M 1.69%
+94,700
New +$8.17M
OKUR
25
OnKure Therapeutics
OKUR
$154M
$7.11M 1.39%
108,332
+96,246
+796% +$7.75M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Great Point Partners held 56 positions worth $511M, up 0.3% from $509M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners's Q2 2023 filing shows 12 new, 14 increased, 11 reduced and 16 closed positions. Its largest new stake was Zura Bio: 3,295,000 shares worth $27M. The largest sale was Jazz Pharmaceuticals, an estimated $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

  • Great Point Partners's largest Q2 2023 buy was Zura Bio: 3,295,000 shares worth $27M.
  • Great Point Partners added most to Rhythm Pharmaceuticals in Q2 2023, an estimated $12.2M increase.
  • Great Point Partners's biggest Q2 2023 reduction was Travere Therapeutics, cutting an estimated $17.2M.
  • Great Point Partners fully exited Jazz Pharmaceuticals in Q2 2023, selling an estimated $21.9M.
  • Great Point Partners's ten largest holdings make up 52% of its $511M portfolio in Q2 2023.
  • Great Point Partners opened 12 new positions and closed 16 in Q2 2023.
  • Great Point Partners's portfolio value rose 0.3% quarter-over-quarter to $511M.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.